GIANNI SOLDATI, Ph. D.,
Founder and President of the Swiss Stem Cell Foundation, Chief Science Officer.

In 1991, Dr. Soldati obtained his Ph. D in molecular biology at the University of Basel. In 2005 he founded Swiss Stem Cell Bank in Lugano, Switzerland. Dr. Soldati is the founder and President of the Swiss Stem Cell Foundation, a foundation dedicated to applied human cell therapy research.

Dr. Soldati’s publications include studies on adipose-derived stem cells (ADSCs), stromal vascular fraction (SVF), and micro fragmented adipose tissue.

Dr. Soldati heads the Ambrose Scientific Advisory Board. After reviewing Ambrose’s ADRC-based Therapy for Rare Genetic Disorders white paper, he stated,  “The hypothesis that ADRCs could modulate gene expression via epigenetic regulation should be evaluated in rigorous clinical trials.”

BRUNO PEAULT, Ph.D. Professor UCLA
Ambrose Scientific Advisory Board Member

In 1987. Dr. Peault earned his Ph.D. in Embryology from the University of Paris. He completed a post-doctoral fellowship at Stanford University Medical Center under Prof. Irving Weissman (1987 -1992)

His education and studies have shaped him into a leader in his field, driven by a strong interest and focus on identification, purification and functional characterization of multi-lineage stem cells present in human adult organs and tissues.

The California Regenerative Medicine Institute awarded Dr. Peault and colleagues a $5.4 million grant to research Harnessing native fat-residing stem cells for bone regeneration.

Dr. Peault’s publications include studies on adipose tissue, ADSCs, SVF, hematology, embryology, and muscle and bone regeneration.

As a member of the Ambrose Scientific Advisory Board, he has identified and acknowledged the remarkable therapeutic effect of autologous ADRC transplantation for diverse rare genetic diseases in addition to wound healing and immunomodulatory mechanisms, stating 

“An FDA-approved clinical trial that includes advanced cell sample testing before and after ADRC infusion to test the hypothesis that ADRCs induce epigenetic modifications that are responsible – at least in part – for clinical improvement in rare disease patients is called for.”

MARY FARACH-CARSON, Ph.D., Professor Rice University

Dr. Farach-Carson obtained her PhD in biochemistry from the Medical College of Virginia at Virginia Commonwealth University in 1982. She served as a postdoctoral fellow at the Johns Hopkins School of Medicine and MD Anderson Cancer Center.

Dr. Farach-Carson is an active researcher with a federally and industry-funded laboratory focused on tissue engineering, extracellular matrix and cancer biology. She is a pioneer in the use of complex 3D systems for cell and microtissue culture of both normal and cancerous tissues.

Her scientific leadership and vision for the BioScience Research Collaborative fosters a climate of interdisciplinary and translational research and innovation.

Dr. Farach-Carson’s publications include cancer biology, bone, genetics, extracellular matrix, tissue engineering, and cell therapy for dry mouth.

Following Dr. Farach-Carson’s review of ADRC-based Therapy for Rare Genetic Disorders white paper, she stated,

“As a member of the Ambrose Scientific Advisory Board and a scientist with extensive experience in epigenetic reprogramming of stem cells, the observation of symptom remission in ADRC-treated patients underscores the potential of these cells to profoundly influence physiology and believes this phenomenon presents a critical opportunity for systematic investigation.”